Free Trial

CorMedix (CRMD) 10K Form and Latest SEC Filings 2026

CorMedix logo
$7.76 +0.22 (+2.85%)
As of 02:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest CorMedix SEC Filings & Recent Activity

CorMedix (NASDAQ:CRMD) has submitted 440+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in CorMedix's financial statements. The most recent filing was a Form SCHEDULE 13G/A submitted on May 15, 2026.

8-K
CorMedix Files Current Report on May. 14, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
CorMedix Files Quarterly Report on May. 14, 2026

The 10-Q contains CorMedix's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

CorMedix SEC Filing History

Browse CorMedix's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/15/2026 7:39 AM
CorMedix (1410098) Subject
Deep Track Capital, LP (1856083) Filed by
Form SCHEDULE 13G/A
05/14/2026 7:00 AM
CorMedix (1410098) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/14/2026 6:34 AM
CorMedix (1410098) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2026 3:16 PM
CorMedix (1410098) Filer
Form DEF 14A
04/29/2026 3:18 PM
CorMedix (1410098) Filer
Form DEFA14A
04/29/2026 3:20 PM
CorMedix (1410098) Filer
Form ARS
04/27/2026 7:05 AM
CorMedix (1410098) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/17/2026 3:15 PM
CorMedix (1410098) Filer
Form PRE 14A
03/26/2026 4:49 PM
CorMedix (1410098) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/05/2026 7:32 AM
CorMedix (1410098) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/05/2026 6:47 AM
CorMedix (1410098) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/06/2026 8:30 PM
CorMedix (1410098) Issuer
Todisco Joseph (1774807) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/06/2026 8:30 PM
CorMedix (1410098) Issuer
Hurlburt Elizabeth (1735256) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/06/2026 8:30 PM
CorMedix (1410098) Issuer
Zelnick Kaufman Beth (2004480) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 8:30 PM
CorMedix (1410098) Issuer
Stewart Robert A (1476493) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 8:30 PM
CorMedix (1410098) Issuer
Duncan Gregory Scott (1831127) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 8:30 PM
CorMedix (1410098) Issuer
DUNTON ALAN W (1304773) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 8:30 PM
CorMedix (1410098) Issuer
Lefkowitz Steven W (1313149) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 8:30 PM
CorMedix (1410098) Issuer
Dillione Janet (1489798) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 8:30 PM
CorMedix (1410098) Issuer
Kaplan Myron (1672645) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 8:30 PM
CorMedix (1410098) Issuer
Todisco Joseph (1774807) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 8:30 PM
CorMedix (1410098) Issuer
Hurlburt Elizabeth (1735256) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 8:30 PM
CorMedix (1410098) Issuer
Zelnick Kaufman Beth (2004480) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 8:31 PM
Blum Susan (1792253) Reporting
CorMedix (1410098) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/22/2026 8:30 PM
CorMedix (1410098) Issuer
Dillione Janet (1489798) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:42 PM
CorMedix (1410098) Subject
Dillione Janet (1489798) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/20/2026 8:28 AM
CorMedix (1410098) Issuer
Todisco Joseph (1774807) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/20/2026 8:28 AM
CorMedix (1410098) Issuer
Hurlburt Elizabeth (1735256) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2026 8:25 PM
CorMedix (1410098) Issuer
Seckler Michael David (2105167) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/15/2026 8:30 PM
CorMedix (1410098) Issuer
Seckler Michael David (2105167) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 8:30 PM
CorMedix (1410098) Issuer
Lefkowitz Steven W (1313149) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 7:15 AM
CorMedix (1410098) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/06/2026 8:30 PM
CorMedix (1410098) Issuer
Zelnick Kaufman Beth (2004480) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 8:30 PM
CorMedix (1410098) Issuer
Hurlburt Elizabeth (1735256) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 8:30 PM
CorMedix (1410098) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 8:30 PM
CorMedix (1410098) Issuer
DUNTON ALAN W (1304773) Reporting
DUNTON ALAN W (1304773) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 10:53 AM
CorMedix (1410098) Subject
SHAIBATALHAMD AYMEN ABDALKADER (2063837) Filed by
Form SCHEDULE 13G/A
12/30/2025 3:28 PM
CorMedix (1410098) Subject
DUNTON ALAN W (1304773) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/19/2025 8:30 PM
CorMedix (1410098) Issuer
Todisco Joseph (1774807) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 3:35 PM
CorMedix (1410098) Subject
Todisco Joseph (1774807) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/11/2025 7:38 AM
CorMedix (1410098) Issuer
Dillione Janet (1489798) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
ZENA Surges: 558% Revenue Growth Fuels Breakout Small-Cap Narrative! (Ad)

ZenaTech (NASDAQ: ZENA) reported $12.9 million in full-year 2025 revenue, representing 558% year-over-year growth, with its Drone-as-a-Service segment contributing $10.1 million of that total. Q3 revenue alone reached $4.35 million - a 1,225% year-over-year increase - as the company expands its AI-driven autonomy platform across surveillance, infrastructure protection, and counter-UAS defense markets. ZENA holds nearly $100 million in total assets and is scaling through active acquisitions.tc pixel

Learn why ZENA is gaining attention as a high-growth AI defense company
12/10/2025 8:38 PM
CorMedix (1410098) Issuer
Lefkowitz Steven W (1313149) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 3:43 PM
CorMedix (1410098) Subject
Dillione Janet (1489798) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/09/2025 3:27 PM
CorMedix (1410098) Subject
Lefkowitz Steven W (1313149) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/04/2025 8:30 PM
CorMedix (1410098) Issuer
Dillione Janet (1489798) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/26/2025 8:30 PM
CorMedix (1410098) Issuer
Dillione Janet (1489798) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/24/2025 3:14 PM
CorMedix (1410098) Subject
Dillione Janet (1489798) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/18/2025 8:45 PM
CorMedix (1410098) Issuer
Dillione Janet (1489798) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 11:54 AM
CorMedix (1410098) Subject
Dillione Janet (1489798) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/12/2025 7:21 AM
CorMedix (1410098) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/12/2025 6:42 AM
CorMedix (1410098) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/10/2025 4:10 PM
CorMedix (1410098) Subject
Mistry Erin (1962774) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/27/2025 8:30 PM
CorMedix (1410098) Issuer
Kaplan Myron (1672645) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 7:21 AM
CorMedix (1410098) Filer
Form DEF 14A
10/20/2025 7:10 AM
CorMedix (1410098) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/14/2025 4:22 PM
CorMedix (1410098) Filer
Form PRER14A
10/07/2025 4:08 PM
CorMedix (1410098) Filer
Form RW
10/07/2025 4:11 PM
CorMedix (1410098) Filer
Form S-3ASR
10/03/2025 6:08 PM
CorMedix (1410098) Filer
Form RW
10/03/2025 6:09 PM
CorMedix (1410098) Filer
Form S-3ASR
09/30/2025 4:15 PM
CorMedix (1410098) Filer
Form S-3
Registration statement under Securities Act of 1933  
09/18/2025 8:45 PM
CorMedix (1410098) Issuer
Duncan Gregory Scott (1831127) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/16/2025 8:45 PM
CorMedix (1410098) Issuer
DUNTON ALAN W (1304773) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/15/2025 4:22 PM
CorMedix (1410098) Filer
Form PRE 14A
09/12/2025 8:45 PM
CorMedix (1410098) Issuer
Todisco Joseph (1774807) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/12/2025 8:30 PM
CorMedix (1410098) Filed by
TALPHERA, INC. (1427925) Subject
Form SCHEDULE 13D
09/12/2025 8:30 PM
CorMedix (1410098) Reporting
TALPHERA, INC. (1427925) Issuer
Form 3
Initial statement of beneficial ownership of securities  
09/12/2025 8:31 PM
CorMedix (1410098) Issuer
Todisco Joseph (1774807) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/12/2025 3:31 PM
CorMedix (1410098) Subject
Todisco Joseph (1774807) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/12/2025 3:37 PM
CorMedix (1410098) Subject
DUNTON ALAN W (1304773) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/11/2025 8:45 PM
CorMedix (1410098) Issuer
Hurlburt Elizabeth (1735256) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/11/2025 8:45 PM
CorMedix (1410098) Issuer
Zelnick Kaufman Beth (2004480) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/09/2025 3:51 PM
CorMedix (1410098) Subject
Hurlburt Elizabeth (1735256) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/09/2025 3:52 PM
CorMedix (1410098) Subject
Zelnick Kaufman Beth (2004480) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/08/2025 6:02 AM
CorMedix (1410098) Issuer
Zelnick Kaufman Beth (2004480) Reporting
Form 4/A
09/08/2025 6:07 AM
CorMedix (1410098) Issuer
Hurlburt Elizabeth (1735256) Reporting
Form 4/A
09/03/2025 4:09 PM
Blum Susan (1792253) Reporting
CorMedix (1410098) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 4:11 PM
CorMedix (1410098) Issuer
Zelnick Kaufman Beth (2004480) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 4:12 PM
CorMedix (1410098) Issuer
Hurlburt Elizabeth (1735256) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/03/2025 3:51 PM
Blum Susan (1792253) Reporting
CorMedix (1410098) Issuer
Form 3
Initial statement of beneficial ownership of securities  
09/03/2025 3:32 PM
CorMedix (1410098) Subject
David Matthew T (1811612) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/02/2025 7:57 AM
CorMedix (1410098) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/12/2025 3:43 PM
CorMedix (1410098) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/08/2025 10:26 AM
CorMedix (1410098) Subject
SHAIBATALHAMD AYMEN ABDALKADER (2063837) Filed by
Form SCHEDULE 13G/A
08/07/2025 7:51 AM
CorMedix (1410098) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/07/2025 6:31 AM
CorMedix (1410098) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/30/2025 3:44 PM
CorMedix (1410098) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/30/2025 7:19 AM
CorMedix (1410098) Filer
Form 424B5
06/26/2025 3:17 PM
CorMedix (1410098) Filer
Form 424B5
06/25/2025 5:07 AM
CorMedix (1410098) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/23/2025 6:51 AM
CorMedix (1410098) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
Read this warning immediately (Ad)

Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel

Read Porter Stansberry's full breakdown and protect your wealth now
(Data available from 1/1/2016 forward)

CorMedix SEC Filings - Frequently Asked Questions

CorMedix (CRMD) has submitted 440+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

CorMedix's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on CorMedix's financial statements page.

The most recent filing was a Form SCHEDULE 13G/A submitted on May 15, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:CRMD) was last updated on 5/18/2026 by MarketBeat.com Staff.
From Our Partners